DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox

The DiagRaMIE project is designed to aid in the prevention and control of emerging or re-emerging infectious diseases and to support effective responses to potential new pandemics. Its main objective is to develop rapid diagnostic immunological tests (RDTs) for priority pathogens identified by the WHO, including the Mpox virus. Recently, monkeypox (Mpox) cases have been reported concurrently in non-endemic countries (Europe and America) and endemic regions (West and Central Africa). In response, the CEA and NG Biotech have developed an RDT to help curb potential transmission. Since its deployment, the number of cases in Europe has dropped considerably, though Mpox remains a significant health concern in Africa, especially in the Democratic Republic of Congo (DRC). This clinical performance study aims to validate a reliable diagnostic tool for both ongoing and potential future Mpox epidemics.

Objectives of the Clinical Performance Study The primary goal of this clinical performance study is to prospectively assess the effectiveness of the NG-TestⓇ Monkeypox virus kit, an RDT developed by CEA and NG Biotech, in diagnosing suspected Mpox cases. The test is based on prospective immunochromatography, with this study serving to support its CE marking.

Primary Evaluation Endpoint The primary endpoint is the participant's Mpox virus infection status, determined through PCR testing using the Xpert® Mpox kit (Cepheid), which is the reference diagnostic test (Gold Standard).

Study Design This is a prospective, multicenter study aimed at validating the diagnostic accuracy of the new RDT. Participants will include symptomatic patients suspected of Mpox infection. Each participant will undergo both the reference PCR test (Xpert® Mpox kit, Cepheid) and the newly developed RDT by CEA and NG Biotech.

Target Population Patients presenting at health facilities with signs and symptoms suggestive of Mpox will be prospectively recruited by healthcare workers. After providing information about the study and obtaining consent (from either the patient or legal guardians for minors), demographic and medical data will be collected, and two samples of vesicular exudate will be taken in addition to the routine diagnostic samples. Number of subjects declared to the insurer (having signed consent): maximum 197 patients in order to have 167 evaluable patients International Research Scope This international study will take place in the Democratic Republic of Congo, specifically in regions with high disease incidence: South Kivu, Equateur, and South Ubangi. Initially, the protocol will focus on these regions. However, if outbreaks emerge elsewhere, the study may be expanded to include additional affected areas, with participants recruited from those regions as well.

Study Duration The clinical study is planned to last for six months.

Inclusion criteria

• Any person showing signs and symptoms, vesicles, and pustules consistent with the WHO definition of suspected Mpox cases (https://www.who.int/fr/publications-detail/WHO-MPX-Surveillance-2022.3)
• Persons aged 2 years and older:
• An adult capable of providing informed consent to participate in the study
• The legal guardian(s) capable of providing informed consent for the minor's participation in the study. For minors aged 12 to 17, their assent will also be required

Exclusion criteria

• Refusal to participate by the individual or their legal guardian(s)
• Person not capable of giving informed consent
• Person with symptoms that appeared more than 14 days ago
• Person presenting only with macules, papules, and crusts